Forebrain neurogenesis persists throughout life in the rodent subventricular zone (SVZ) and hippocampal dentate gyrus (DG). Several strategies have been employed to eliminate adult neurogenesis and thereby determine whether depleting adult-born neurons disrupts specific brain functions, but some approaches do not specifically target neural progenitors. We have developed a transgenic mouse line to reversibly ablate adult neural stem cells and suppress neurogenesis. The nestin-tk mouse expresses herpes simplex virus thymidine kinase (tk) under the control of the nestin 2nd intronic enhancer, which drives expression in neural progenitors. Administration of ganciclovir (GCV) kills actively dividing cells expressing this transgene. We found that peripheral GCV administration suppressed SVZ-olfactory bulb and DG neurogenesis within 2 weeks but caused systemic toxicity. Intracerebroventricular GCV infusion for 28 days nearly completely depleted proliferating cells and immature neurons in both the SVZ and DG without systemic toxicity. Reversibility of the effects after prolonged GCV infusion was slow and partial. Neurogenesis did not recover 2 weeks after cessation of GCV administration, but showed limited recovery 6 weeks after GCV that differed between the SVZ and DG. 
1999), and expression of GFAP outside the central nervous system results in systemic toxicity following GCV administration (Bush et al., 1998) .
Bearing in mind the goal of ablating adult neurogenesis without altering the brain's response to injury and disease, or producing systemic toxicity that might affect behavioral performance, we have generated a transgenic mouse expressing HSV-tk from the 2nd intronic 
MATERIALS AND METHODS Animals
The tk gene from HSV type 1, with the DNA sequence of the viral gene modified by humanizing the usage codon and eliminating all the CpGs (pMod-TK, Invitrogen, Carlsbad, CA), was fused downstream of a minimal TK promoter element followed by a 1.8-kb fragment of the 2nd intronic nestin enhancer (Fig.  1A ) (Yaworsky and Kappen, 1999) . The insert was purified for pronuclear injection by the Transgenic Core at the University of Michigan Diabetes Research and Training Center, and 13 founders from two separate injections were generated on an FVB background. The mice appeared healthy with normal growth and reproduction. Mice were genotyped by polymerase chain reaction (PCR), and nestin-tk ؉ mice and wild-type littermate controls were 8 -12 weeks of age at the onset of treatment. All procedures involving animals were approved by the University Committee on the Use and Care of Animals of the University of Michigan. free medium as a control; 2) in medium containing 9 M GCV for 24 hours and then in GCV-free medium for 4 days; or 3) in medium containing 9 M GCV for 5 days. At the end of the 5-day culture period, NS were measured and counted based on their diameters: small (<0.1 mm), medium (0.1-0.8 mm), and large (>0.8 mm).
In vivo GCV administration
For pilot studies, 100 mg/kg GCV (Cytovene, Roche, Indianapolis, IN) or 100 mg/kg elaidic acid esterified GCV (eGCV CP-4018, Clavis Pharma, Oslo, Norway; Balzarini et al., 1998) was administered daily via intraperitoneal (i.p.) injection. To improve penetration of the blood-brain barrier, eGCV was prepared in a liposomal solution according to the manufacturer's instructions. Briefly, a solution of eGCV (25 mg/ml) and phosphotidyl choline (100 mg/ml; Sigma) in ethanol was rapidly injected into water. The resulting suspension was then frozen (؊80°C) and lyophilized. The dried product was resuspended in a solution of glycerol and water (22.4 mg/ml) and briefly sonicated. In some experiments, osmotic minipump (Alzet, Cupertino, CA, model 2004) subcutaneous infusion was used as described previously ).
Due to the adverse systemic effects of i.p. or subcutaneous GCV and eGCV administration, for all subsequent experiments we administered GCV via ICV infusion at a rate of 0.25 l/hr by using an osmotic minipump. Minipumps (Alzet, model 2004) were filled with 20 mM GCV or normal saline and primed for 36 hours at 37°C. For implantation of the pump and cannula, mice were anesthetized with 130 mg/kg ketamine and 20 mg/kg xylazine and fixed to a stereotaxic frame after loss of the paw withdrawal reflex. The osmotic pump was implanted subcutaneously over the scapulae, and fitted to an intraventricular cannula (Brain Infusion Kit 3, Alzet) implanted 0.21 mm anterior, 0.85 mm lateral, and 3.0 mm deep to Bregma. Following surgery, all mice were housed individually for the remainder of the experiment.
Bromodeoxyuridine labeling and tissue processing
Pulse bromodeoxyuridine (BrdU) labeling was used to identify mitotically active cells. BrdU (100 mg/kg) dissolved in phosphate-buffered saline (PBS; pH 7.4) was administered once by i.p. injection, and 2 hours later animals were killed by anesthetic overdose. Brains were perfusion-fixed with 0.9% NaCl, followed by 4% paraformaldehyde (PFA) in phosphate buffer. In another set of experiments, BrdU was given once daily on days 10 -12 after the start of the ICV infusion of GCV, and animals were killed at the end of the 28-day infusion. Brains were removed and postfixed overnight in 4% PFA, cryoprotected with 30% sucrose, embedded in freezing medium, frozen in dry ice and 2-methyl butane, and sectioned coronally at 50-m thickness.
Immunohistochemistry
For immunofluorescence labeling, sections were rinsed in Tris-buffered saline (TBS; pH 7.4) and incubated in blocking buffer for 1 hour prior to incubation with primary antibody. After three TBS washes, sections were incubated with Alexa Fluor 594-or 488-conjugated goat anti-mouse, -rat, or -rabbit IgG secondary antibody (1:400; Molecular Probes, Eugene, OR) at room temperature for 2 hours, washed three times with TBS, mounted on slides, and coverslipped with antifade medium (Pro-Long; Molecular Probes). For BrdU immunofluorescence, sections were incubated with 2 N HCl at 37°C for 30 minutes to denature the DNA and then neutralized with 0.1 M sodium borate (pH 8.5) for 10 minutes. After TBS washes, sections were incubated with rat anti-BrdU (1:200; Accurate Chemical, Westbury, New York) at 4°C overnight and then processed as described above.
For diaminobenzidine (DAB) staining, sections were processed as follows: rinses with Tris buffer, deactivation of endogenous peroxidases with 1% H 2 O 2 , rinses with Tris buffer containing Triton X-100/bovine serum albumin (Tris-B), blocking with 10% normal goat serum in Tris-B for 1 hour, and then incubation with primary antibody at 4°C overnight (see below). After Tris buffer washes, sections were incubated with biotinylated horse anti-goat IgG (1:200; Jackson ImmunoResearch, West Grove, PA) and then avidin-biotin peroxidase (ABC) complex (Vector, Burlingame, CA). For color reaction, sections were incubated with stable DAB (Invitrogen), rinsed three times, mounted on slides, and coverslipped with Permount medium. For BrdU immunohistochemistry, sections were incubated with 2 N HCl at 37°C for 30 minutes to denature the DNA, and then neutralized with 0.1 M sodium borate (pH 8.5) for 10 minutes. After Tris washes, sections underwent peroxidase deactivation, rinsing, and blocking as above and incubation with mouse anti-BrdU (1:1,000, Roche) overnight at room temperature. After Tris washes, sections were incubated with biotinylated horse anti-mouse IgG (1:200; Jackson ImmunoResearch) and processed with ABC complex and DAB as above. Images were captured with a Leica DSM-IRB epifluorescence microscope and Spot-RT digital camera or, for double labeling, as a z-series of thin optical sections with a Zeiss LSM-510 confocal microscope. Digital images were imported into Adobe Photoshop v.6.0 (Adobe Systems, Mountain View, CA). Contrast and brightness were adjusted slightly to keep background intensity levels comparable among animals.
Antibody characterization
The monoclonal mouse anti-BrdU antibody (Roche, 1170376) was prepared against a BrdU-bovine serum albumin conjugate; it cross-reacts with iodouridine at 10% of the intensity of BrdU, but not fluorodeoxy-uridine, nor with any endogenous cellular components such as thymidine or uridine (manufacturer's information). Antibody was used at 1:1,000 titer, and staining was absent in tissue from mice not injected with BrdU. The monoclonal rat anti-Brdu antibody (Accurate Chemical, OBT0030CX) was prepared against iodouridine conjugated to bovine serum albumin; it does not cross-react with thymidine (manufacturer's information; Vanderlaan and Thomas, 1985) . Antibody was used at 1:200 titer, and staining was absent in tissue from mice not injected with BrdU.
The polyclonal goat anti-doublecortin (DCx) antibody (Santa Cruz Biotechnology, Santa Cruz, CA; sc-8066, C-18 clone) was prepared against the C-terminal of a synthetic DCx peptide corresponding to amino acids 385-402 at the C-terminus of human DCx (Swiss-Prot #O43911). The anti-DCx sc-8066 antiserum recognizes a 45-kDa band by Western blot of human DCx-transfected 3T3-L1 whole cell lysate, does not react to lysate of untransfected cell lines, and is specific to DCx of mouse, rat, and human origin by Western blotting, immunoprecipitation, and immunohistochemistry; it does not crossreact with a related protein, KIAA0369 (manufacturer's information). The pattern of C-18 staining observed was consistent with that of previous studies that have examined birth-dating of DCx-immunoreactive neurons (Brown et al., 2003) . Antibody was used at 1:2,000 titer.
The monoclonal mouse anti-GFAP antibody (Sigma; G3893, G-A-5 close) was prepared against GFAP purified from pig spinal cord; it recognizes GFAP-containing astrocytes and a 50-kDa protein on Western blots (manufacturer's information; Latov et al., 1979) . Antibody was used at 1:500 titer.
The polyclonal rabbit anti-glucose transporter 1 (GLUT1) antibody (Chemicon, Temecula, CA; AB1340) was prepared against a synthetic peptide corresponding to amino acids at the C-terminus (C-ELFHPLGADSQV) of rat GLUT-1 (SwissProt #P11166) coupled to keyhole limpet hemocyanin (KLH). It recognizes both the 55-and 45-kDa forms of GLUT1 on Western blot and does not react to colorectal cancer controls; it recognizes GLUT1 in human, mouse, and rat tissue (manufacturer's information; Smoak and Branch, 2000) . Antibody was used at 1:800 titer.
The polyclonal rabbit anti-Ki67 antibody (Vector; VP-K451) was prepared against an isolated 20-mer peptide (NH2-AGGDEKDIKAFMGTPVQKLD-COOH) corresponding to a 62-bp cDNA containing the Ki67 motif (Key et al., 1993a,b) . This rabbit antiserum was shown to detect 345-and 395-kDa bands on Western blot of lysed IM-9 cells, the same bands detected by the monoclonal Ki-67 antibody used to define the motif. The antibody was used at 1:500 titer and resulted in nuclear staining in proliferative brain regions consistent with that observed by other authors (Maslov et 
Cell counting
Stereological estimates of cell number were performed with a computer-aided microscopy system (Visiopharm, Horsholm, Denmark) coupled to an Olympus BX51 microscope. Due to the low total number of labeled cells in each section, the entire region of interest in every 12th section through the DG contralateral to the site of ICV cannula implantation was examined at high power by using a 60؋, NA 1.35 oil immersion objective. In sections labeled for DCx, the region of interest comprised the entire granule cell layer of any section with a discernible border between the DGC layer and dentate hilus. In sections labeled for BrdU, the region of interest extended from the inner half of the DGC layer and penetrated two granule cell body widths into the dentate hilus. Blinded cell counts were then estimated by using an optical fractionator probe ( 
Tail suspension test
Mice were implanted with an ICV cannula and received a continuous infusion of GCV for 28 days as previously described. Fourteen days after implantation, mice were injected (i.p.) once daily for 28 days with a single dose of imipramine (3, 10, or 30 mg/kg) or saline. Thirty minutes after the last imipramine dose, each mouse was evaluated in the tail suspension test. For this behavioral assay, tape was attached to the bottom half of each mouse's tail, and then it was secured to a metal pole suspended approximately 8 inches from a table surface. The mouse remained suspended and was videotaped for 6 minutes. The videotape was later scored for duration of immobility by one or two observers blind to the drug treatment and genotype; interscorer reliability was greater than 90%. Immobility was defined as continuous periods of stillness, with an occasional small movement or isolated twitch allowed. Following the tail suspension test, brain tissue from each mouse was perfused and fixed as previously described. Imipramine was dissolved and diluted in saline, and all injections were administered in a volume of 1 ml/100 g of body weight.
Statistics
Comparisons among cell or NS counts in multiple treatment groups were performed by using one-way ANOVA, with post hoc t-tests and groupwise contrasts adjusted for multiple comparisons by Tukey's criterion. When appropriate, pairwise comparisons were made by using Student's t-test. All tests were two-tailed. Analyses of cell counts were performed by using SPSS 15 software (SPSS, Chicago, IL). Behavioral data were analyzed by one-or two-way ANOVA with Dunnett's post hoc test (Graphpad Prism [La Jolla, CA] software). If no interaction was observed, post hoc analyses were conducted on significant main effects. Data are presented as the mean plus 1 SEM, and P < 0.05 was accepted as statistically significant.
RESULTS

GCV suppresses nestin-tk
؉ cell proliferation in vitro Cultures derived from wild-type mice produced similar numbers of NS regardless of whether they were grown in GCV-free media or in media containing 9 M GCV for 24 hours or for the entire 5-day culture period (Fig. 1B-E) . Cultures from nestin-tk ؉ mice, however, produced significantly fewer small and medium-sized secondary NS when exposed to GCV for either 24 hours or 5 days than when grown in basal media, or when compared with wild-type derived cultures grown with GCV (F(17,54) ‫؍‬ 355.7, P < 0.001; Fig. 1B-H) . The number of large nestin-tk ؉ NS was also reduced in the presence of GCV compared with wild-type cultures treated with GCV and nestin-tk ؉ cultures in basal media, but the difference was not significant. In addition, nestin-tk ؉ cultures in basal media produced slightly, but significantly, fewer NS than wild-type derived cultures under the same conditions (P < 0.001; Fig.  1B,C,F) .
These findings indicate that in vitro treatment with GCV in the presence of the nestin-tk transgene suppresses NS formation from postnatal SVZ-derived neural progenitors. This effect was observed after 5 days of continuous GCV exposure or after 24 hours of GCV exposure followed by 4 days in basal media, suggesting that GCV administration results in a rapid, prolonged ablation of a large portion of the stem cell population in vitro. As expected, GCV did not influence the proliferation of SVZ stem cells derived from wild-type mice. We did note, however, that NS formation was slightly diminished in cultures derived from nestin-tk ؉ mice versus wild-type even in the absence of GCV (Fig. 1B, left side) , raising the possibility that either the transgene product or site of insertion has a deleterious effect on stem cell proliferation.
In the absence of GCV treatment, the nestin-tk transgene does not impair basal cell proliferation and adult neurogenesis in vivo
Before conducting experiments evaluating the effect of GCV on adult neurogenesis in vivo, we examined whether the presence of the nestin-tk transgene alone altered forebrain SVZ and dentate SGZ cytogenesis. Three-month-old mice received a single BrdU injection (100 mg/kg, i.p.), and the pattern of BrdU immunoreactivity was examined 2 hours later. The forebrain SVZ of both untreated wild-type and untreated nestin-tk ؉ mice contained a similar pattern of large numbers of BrdU-immunoreactive nuclei ( Fig. 2A,B) . The dentate SGZ contained clusters of BrdU-labeled cells (Fig. 2E,F (Fig. 2C,D,H,I ). There was no significant difference in the number of DCx ؉ cells in the DG of wild-type and nestin-tk ؉ mice ( Fig. 2J ; P > 0.5, n ‫؍‬ 6/group). Thus, despite the small disparity in proliferative potential among nestin-tk ؉ and wild-type NS observed in vitro, the presence of the nestin-tk transgene does not reduce the rates of cell division or neurogenesis in vivo in the main neurogenic regions of the adult brain. Additional studies using other nestin-tk mouse lines would be helpful to establish the reason for the differences we found in vitro.
Systemic GCV administration in adult nestin-tk
؉ mice suppresses SVZ and SGZ cell proliferation
To determine whether GCV treatment would effectively reduce neurogenesis in nestin-tk ؉ mice in vivo, we first examined the effect of systemically administered GCV on cytogenesis in the SVZ and SGZ. Adult mice received a liposomal solution of eGCV for 14 days (100 mg/kg/d, i.p.). On the day after eGCV treatment ended, a single pulse of BrdU (100 mg/kg) was administered, and BrdU immunoreactivity was examined 2 hours later. Although the SVZ and SGZ of wildtype animals treated with eGCV showed robust BrdU labeling commensurate with untreated controls (Fig. 2K,M) , BrdU labeling was dramatically reduced in nestin-tk ؉ mice after eGCV treatment (Fig. 2L,N) . Similarly, nestin immunoreactivity in the SVZ was virtually absent after eGCV administration in nestin-tk ؉ mice (Fig. 2O,P) . Comparable findings were seen after GCV was administered subcutaneously (data not shown). These results indicate the potential of systemic GCV administration in nestin-tk ؉ mice to achieve cytostasis in neurogenic regions, and indeed to deplete the population of nestinexpressing progenitor cells.
Peripheral administration of either GCV or eGCV in a concentration and duration sufficient to suppress cell division in the SVZ and SGZ, however, also resulted in significant systemic toxicity. Nestin-tk ؉ mice lost up to 30% of their body weight and suffered 100% mortality by 16 days after the initiation of GCV or eGCV administration. The mortality that accompanied GCV treatment may relate to ablation of nestinexpressing pancreatic cells, as we found that the weight of the pancreatic mass in nestin-tk ؉ mice was reduced by over 50% after GCV treatment compared with GCV-treated wild-type controls (data not shown). Despite multiple experiments varying GCV and eGCV concentrations, administration rate, and peripheral administration route, including subcutaneous osmotic minipump infusion (Garcia et al., 2004 ), we were unable to achieve effective concentrations of GCV in the brain without causing systemic toxicity.
ICV infusion of GCV ablates proliferation and neurogenesis in the SVZ and SGZ
We sought to take advantage of the limited capacity of GCV to cross the blood-brain barrier (Bodor and Buchwald, 1999) and circumvent systemic effects by infusing GCV directly into the lateral ventricle. Mice were implanted with an ICV cannula and received a continuous infusion of 2 mM GCV or saline vehicle for 28 days via osmotic minipump (n ‫؍‬ 7 tk ؉ ؉ GCV, 5 tk ؉ ؉ vehicle, 4 wild-type ؉ vehicle). The 28-day infusion duration was chosen to eliminate an extensive cohort of adultborn neurons over the time that they would begin to integrate, 2-4 weeks (reviewed in Ming and Song, 2005), in preparation for later behavioral studies. Utilizing this administration route, we did not observe any differences in the overt behavior of wild-type or nestin-tk ؉ mice, and there was no mortality following GCV administration. In addition, the weights of the mice did not differ after GCV infusion (wild-type: mean 31.1 ؎ 1.6 g; nestin-tk ؉ : mean 29.9 ؎ 1.2 g, P > 0.5, n ‫؍‬ 12/group).
Following 28 days of ICV infusion, we examined proliferation and neurogenesis in the SVZ-olfactory bulb pathway and hippocampal DG. The number of mitotically active cells in the SVZ labeled by the cell-cycle protein Mcm2 (Maslov et al., 2004) was greatly reduced in nestin-tk
؉ mice after GCV administration (Fig. 3C ) compared with vehicle-treated transgenic and GCV-treated wild-type controls (Fig. 3A,B) . We observed the same result by using Ki67 labeling as a marker of cell proliferation (data not shown). This reduction in precursor proliferation was further reflected in the complete loss of DCx-immunoreactive neuroblasts in the SVZ (Fig. 3D-F ) and olfactory bulb (Fig. 3Gb-I ) of nestin-tk ؉ mice following GCV treatment.
The suppression of neurogenesis was also effective in the DG. After 28 days of GCV treatment, the SGZ of nestin-tk ؉ mice was nearly completely devoid of proliferating cells labeled by Mcm2 (Fig. 4A-C) or Ki67 (data not shown). The 
-D), E (applies to E,F,H,I), K (applies to K,L), and 100 m in M (applies to M,N) and O (applies to O,P).
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The Journal of Comparative Neurology 572 B.H. SINGER ET AL. double labeling for BrdU and the mature neuronal marker NeuN by confocal microscopy showed that about 50% of BrdU-labeled cells co-expressed NeuN in wild-type controls treated with GCV, whereas no double labeling was found in GCV-treated, nestin-tk ؉ animals ( Fig. 4H,I ; n ‫؍‬ 3 mice/group). Furthermore, we did not observe any differences in GFAP and Glut1 immunoreactivity in the DG among nestin-tk ؉ and wildtype mice treated with GCV, suggesting that the loss of mitotically active precursors does not elicit frank gliosis or vascular changes in the hippocampus (data not shown; Latov et al., 1979; Smoak and Branch, 2000) . Further supporting a lack of inflammatory response in nestin-tk ؉ mice treated with GCV, we found no increase in activated microglia by ED-1 immunostaining except along the cannula track, and the degree was similar between treatment and control groups.
These results demonstrate that ICV administration of GCV for 28 days leads to a dramatic reduction in cellular proliferation in both neurogenic regions of the adult mouse brain.
Moreover, this loss of proliferation leads to a nearly complete depletion of DCx-immunoreactive cells in both the olfactory bulb and DG. Because immature neurons express DCx for several weeks following their birth, their absence suggests that neurogenesis is suppressed rapidly and that the suppression is maintained for the duration of GCV administration (Brown et al., 2003) . Depletion of adult-born neurons was further suggested by the absence of double labeling for BrdU and the mature neuronal marker NeuN.
Proliferation and neurogenesis recover slowly after cessation of GCV administration
The nearly complete ablation of neurogenesis following 28 days of GCV administration suggests that the pool of nestinexpressing progenitor cells may be gradually depleted as they enter the cell cycle. To study the capacity of the remaining SVZ and SGZ progenitors to restore newborn neurons to the olfactory bulb and DG after a period of suppression, we ter- 
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The Journal of Comparative Neurology 575 INDUCIBLE ABLATION OF NEUROGENESIS minated GCV administration after 28 days and examined mice following a 2-week or 6-week recovery period. Following 2 weeks of recovery after GCV treatment, no DCx-labeled neuroblasts or interneurons were observed in either the SVZ or OB, respectively, in nestin-tk ؉ mice (Fig. 5A-D) . Similarly, the DG was devoid of DCx-immunoreactive cells in nestin-tk ؉ mice compared with wild-type animals ( Fig. 5E-G ; P < 0.001; n ‫؍‬ 3/group).
The lack of DCx-labeled cells in either the SVZ or DG after 2 weeks of recovery could reflect complete ablation of the neural progenitor population, or could result from the relative quiescence of progenitors that survive the death of dividing cells during GCV administration. We therefore examined the SVZ-olfactory bulb pathway and DG 6 weeks after the cessation of GCV to allow for additional expansion and differentiation of the progenitor population. In the SVZ, some cells expressing Mcm2 (Fig. 6A,B) and Ki67 (data not shown) appeared in both nestin-tk ؉ and wild-type control mice following 6 weeks of recovery from GCV treatment. In addition, DCx-immunoreactive neuroblasts were present in the SVZ and olfactory bulb in nestin-tk ؉ mice, albeit at reduced numbers compared with wild-type controls (Fig. 6C-F) .
Proliferating cells and immature neurons also began to repopulate the DG after 6 weeks of recovery (Fig. 7) . However, unlike the recovery of neurogenesis in the SVZ, which was present bilaterally, nascent recovery of neurogenesis was only evident unilaterally in the SGZ. Although Mcm2-and Ki67-labeled cells were present bilaterally in wild-type controls after 28 days of ICV GCV treatment and 6 weeks of recovery ( Fig. 7A ; Ki67, data not shown), they were only evident in nestin-tk ؉ mice in the SGZ contralateral to the side of GCV infusion ( Fig. 7B; Ki67, data not shown) . Similarly, no DCxlabeled cells were present ipsilateral to the infused lateral ventricle, whereas sparse labeling was observed contralaterally (Fig. 7D,E) . Quantification of DCx-immunoreactive cells revealed a significant decrease ipsilaterally ( Fig. 7E; F(2,10) ‫؍‬ 8.34, P < 0.01; n ‫؍‬ 7/group) and a trend toward persistent reduction contralaterally (P < 0.125) compared with GCVtreated, wild-type controls. Nestin and GFAP immunoreactivity persisted in radial glia-like cells in the DG of tk ؉ mice after the 28-day GCV infusion (data not shown), suggesting that type 1 stem-like cells were not entirely eliminated. Thus, the repopulation dynamics after 28 days of GCV administration indicate that some progenitor cells survive throughout the period of GCV infusion and are able to reconstitute neurogenesis, although neurogenesis recurs bilaterally in the SVZ but only in the DG contralateral to the GCV infusion.
Ablation of proliferation and neurogenesis does not alter the antidepressant-like effects of imipramine in vivo
Reductions in forebrain neurogenesis were evaluated in an animal model used to identify antidepressant-like activity, the mouse tail suspension test. In nonimplanted, wild-type FVB mice, chronic imipramine administration dose-dependently decreased immobility in the tail suspension test (F(3,22) ‫؍‬ 9.67, P ‫؍‬ 0.0004; Fig. 8A ). Significant decreases were observed at 10-mg/kg (P < 0.05) and 30-mg/kg (P < 0.001) doses compared with saline treatment. Chronic imipramine administration also decreased immobility in single-housed, GCV-treated wild-type littermate and nestin-tk ؉ mice (main effect for imipramine: F(3,62) ‫؍‬ 13.41, P < 0.0001; Fig 8B) ; however, the nestin-tk transgene did not significantly alter the effects of imipramine (interaction: F(3,62) ‫؍‬ 0.15, P ‫؍‬ 0.93; main effect for nestin-tk transgene: F(1,62) ‫؍‬ 0.014, P ‫؍‬ 0.91). Significant decreases in immobility were observed at 10 mg/kg (P < 0.05) and 30 mg/kg (P < 0.001) compared with saline independent of the transgene. As expected, GCV treatment led to a nearly complete cessation of neurogenesis only in transgenic mice (Fig. 8C,D) . GCV treatment did not markedly attenuate DCx immunoreactivity in two of seven nestintk ؉ mice in the 30-mg/kg imipramine dose group, but exclu- 
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DISCUSSION
Our results indicate that administration of GCV to mice expressing the nestin-tk transgene effectively ablates adult neurogenesis in both the SVZ/OB and SGZ/DG pathways. Infusion of GCV into the lateral ventricle for 28 days led to suppression of cell proliferation in both the SVZ and SGZ, and depletion of immature neuronal populations in the OB and DG. Once ablated, progenitor proliferation was slow to recover even in the absence of continuing GCV administration, and the rate of recovery differed among the neurogenic regions. Two weeks after the cessation of GCV infusion, proliferation recovered in the SVZ but not the SGZ, and no immature neurons were evident in the OB or DG. After an extended recovery period of 6 weeks, both proliferation and immature neurons were present bilaterally in the SVZ/OB pathway, but the SGZ/DG pathway experienced only a partial, unilateral recovery. These results suggest that the dynamics of progenitor proliferation differ significantly among the SVZ and SGZ, although the nature of these differences remains to be determined.
The nestin-tk mouse permits inducible ablation of adult neurogenesis
We sought to produce a model system to facilitate the study of adult neurogenesis and its role in neurophysiology and behavior. Undesired systemic toxicity is a problem common to the GFAP-tk mouse, which utilizes thymidine kinase expression to ablate GFAP-expressing neural progenitors ( Nevertheless, the limited recovery of neurogenesis we observed in both the SVZ and SGZ indicates that some progenitor cells do escape ablation, even after 28 days of GCV treatment. The persistence of radial glia-like cells in the DG after GCV treatment suggests that a subset of type 1 stem-like cells may stop proliferating and thereby avoid GCV-induced death. Also, the asymmetric recovery between ipsilateral and contralateral DG likely resulted from the latter being exposed to a lower GCV concentration, leading to greater recovery, whereas the ipsilateral DG was exposed to higher GCV concentrations similar to those that would be expected in the SVZ after ICV infusion. The greater recovery seen in the SVZ than ipsilateral SGZ suggests that many SGZ progenitors more readily enter the cell cycle and are thus more vulnerable to elimination than their counterparts in the SVZ. Alternatively, the remaining progenitors in the SVZ could proliferate at a higher rate than in the SGZ, leading to faster SVZ recovery. However, unlike mice treated with irradiation to eliminate the cohort of actively dividing cells who then experience a surge in compensatory proliferation in the SVZ (Tada et al., 1999) , nestin-tk ؉ mice seem to possess a limited regenerative capacity and repopulate the neurogenic zones more gradually. A third possibility is that thymidine kinase is incompletely expressed in both progenitor populations, and differentially expressed in the SVZ and SGZ. The complete lack of neurogenesis in nestin-tk ؉ mice 2 weeks after the cessation of GCV infusion, however, argues against a scenario in which a subpopulation of actively dividing progenitors escapes ablation throughout the period of GCV administration.
Role of neurogenesis in antidepressant-like effects
One current theory proposes that hippocampal cell proliferation and neurogenesis are the common therapeutic mechanisms of all known classes of antidepressant drugs. We In addition to its usefulness in studying the role of adult neurogenesis in depression, the nestin-tk mouse offers utility for investigating the functions of adult-born neurons in hippocampal physiology, other behavioral paradigms, and neurological disease models. Furthermore, because the loss of adult-born neurons is not irreversible, this model system will facilitate future investigations of how the neurogenic niche is reconstituted after an insult, such as treatment of brain malignancies (Monje et al., 2007) . Further studies using this mouse will enhance our understanding, not only of the functional role of adult neurogenesis in the brain, but also of the basic dynamics underlying the birth, survival, and death of adult-born neurons.
